Franklin Genomic Advancements ETF Rating $43.46 -1.74 (-3.84%) As of 12:15 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Ratings Stock AnalysisChartDividendHoldingsOwnershipRatings Franklin Genomic Advancements ETF Aggregate Rating and Price Target (2026)How MarketBeat Aggregates ETF Rating and Price TargetMarketBeat calculates the aggregate rating and price target for an ETF by considering the weight of each stock in its portfolio. These ratings and price targets are based on the most recent ratings given by Wall Street analysts over the past year. The aggregate rating reviews the ETF's overall performance and is categorized as strong sell, sell, reduce, hold, moderate buy, buy, or strong buy. The aggegreate price target represents the average potential upside for the consensus price target of individual holdings in the ETF.HELX Aggregate RatingModerate Buy 2.76Holdings in HELX have an aggregate rating of Moderate Buy based on 432 analyst ratings issued in the past year covering 24 companies (74.5% of the portfolio).HELX Aggregate Price Target$43.720.06% UpsideHigh Prediction$43.72Average Prediction$43.72Low Prediction$43.72Holdings in HELX have an aggregate price target of $43.72 and a range of $43.72 to $43.72 covering 24 companies (74.5% of the portfolio).HELX Consensus Ratings of HoldingsStrong Buy0 Strong Buy rating(s)Buy3 Buy rating(s)Moderate Buy16 Moderate Buy rating(s)Hold5 Hold rating(s)Reduce0 Reduce rating(s)Sell0 Sell rating(s)Strong Sell0 Strong Sell rating(s) Ratings for Stocks Held by Franklin Genomic Advancements ETF Strong Sell Sell Reduce Hold Moderate Buy Buy Strong Buy Ratings for the Top 24 HELX Holdings ExportWeight In ETFCompanyShare PriceConsensus RatingConsensus Price TargetPossible UpsideNumber of RatingsMarketRank™Indicator(s)ViewRatings10.22%NTRANatera$403.96-5.1%Moderate Buy$341.55 -15.5%232.2489 of 5 starsTrending NewsAnalyst ForecastInsider Trade9.68%GHGuardant Health$173.64-7.3%Moderate Buy$188.54 8.6%252.0736 of 5 stars5.31%KRYSKrystal Biotech$329.39-1.6%Buy$377.20 14.5%144.347 of 5 starsPositive News4.99%TWSTTwist Bioscience$173.68-15.3%Moderate Buy$115.27 -33.6%121.3618 of 5 starsTrending NewsInsider TradeGap UpHigh Trading Volume4.93%ADPTAdaptive Biotechnologies$27.61-7.5%Moderate Buy$28.94 4.8%81.6696 of 5 starsInsider Trade4.33%LGNDLigand Pharmaceuticals$297.15-3.1%Buy$337.89 13.7%103.4144 of 5 stars2.78%BBIOBridgeBio Pharma$67.48+2.0%Moderate Buy$102.61 52.1%243.0876 of 5 starsNews CoverageAnalyst ForecastGap Up2.71%TVTXTravere Therapeutics$56.55-2.0%Moderate Buy$69.50 22.9%121.8229 of 5 stars2.64%MEDPMedpace$613.33-1.2%Hold$602.27 -1.8%132.3528 of 5 stars2.62%VRTXVertex Pharmaceuticals$502.27-0.2%Moderate Buy$575.13 14.5%233.9301 of 5 stars2.32%CTVACorteva$13.91+12.3%Moderate Buy$73.95 431.5%234.9826 of 5 starsTrending NewsAnalyst ForecastGap UpHigh Trading Volume2.29%LLYEli Lilly and Company$1,160.72+1.5%Moderate Buy$1,311.96 13.0%304.8364 of 5 starsTrending News2.25%TEMTempus AI$74.78-10.5%Hold$71.05 -5.0%222.0048 of 5 starsPositive News2.19%UTHRUnited Therapeutics$540.26+0.7%Moderate Buy$621.00 14.9%143.9349 of 5 stars2.05%REGNRegeneron Pharmaceuticals$734.54+1.1%Moderate Buy$813.67 10.8%264.3442 of 5 starsAnalyst Forecast2.04%RGENRepligen$178.67-5.7%Moderate Buy$168.57 -5.7%182.1935 of 5 stars1.82%GRALGRAIL$140.13-9.1%Hold$102.70 -26.7%121.052 of 5 starsGap Up1.64%CDNACareDx$65.57-6.1%Hold$54.00 -17.6%82.2171 of 5 stars1.47%CRLCharles River Laboratories International$308.88-0.6%Moderate Buy$300.11 -2.8%173.4069 of 5 starsTrending NewsAnalyst RevisionGap Up1.37%NBIXNeurocrine Biosciences$143.03-0.8%Moderate Buy$202.05 41.3%244.6963 of 5 starsAnalyst Forecast1.36%JAZZJazz Pharmaceuticals$231.36-2.0%Buy$291.15 25.8%204.2109 of 5 starsAnalyst DowngradeInsider Trade1.29%TXG10x Genomics$83.20-14.9%Hold$53.93 -35.2%181.493 of 5 starsGap Up1.17%BNTXBioNTech$97.83+0.2%Moderate Buy$126.00 28.8%193.9909 of 5 stars1.05%IQVIQVIA$265.04-0.4%Moderate Buy$264.31 -0.3%173.135 of 5 stars This page (BATS:HELX) was last updated on 10/6/2026 by MarketBeat.com Staff. From Our PartnersThis smart glasses tech is bringing the screen to your eyesGlobal AI smart-glasses shipments surged 263% in the first half of 2026, and Citi projects the market could re...The Tomorrow Investor | SponsoredElon Warns "America Will Go Bankrupt". Trump's Plan Inside.National debt just crossed 40 trillion dollars, and Elon Musk says America is 1,000% going to go bankrupt with...American Hartford Gold | SponsoredFeds Say Your Cash Isn’t Property—Can They Take It?The Department of Justice recently argued in court that cash may not qualify as legal property. That raises...Priority Gold | SponsoredA weekly dividend fund holding Nvidia and PalantirCrowdStrike, Palantir, Nvidia none of them pay a real dividend. But one fund holding the biggest AI names dist...Investors Alley | SponsoredThe case for $20,000 gold before year endPresident Trump reposted a warning from precious metals expert Jim Rickards, tying the November midterms and A...Stansberry Research | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredThey're not telling you how bad this could getValuations have reached levels seen only a handful of times in the past century, while debt concerns and tarif...Parkview Capital Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Franklin Genomic Advancements ETF Please log in to your account or sign up in order to add this asset to your watchlist. Share Franklin Genomic Advancements ETF With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
